CellaVision Earnings Call Highlights Growth, Margin Trade-offs

CellaVision AB ((SE:CEVI)) has held its Q4 earnings call. Read on for the main highlights of the call.

CellaVision Delivers Solid Quarter Despite Margin Headwinds and APAC Weakness

CellaVision’s latest earnings call painted a broadly upbeat picture, with management emphasizing strong organic growth, robust profitability and record performance in the Americas. While foreign exchange headwinds, a weaker product mix in Q4 and a soft quarter in APAC weighed on margins and regional performance, the company underlined continued commercial momentum, a solid balance sheet, and strategic milestones in new applications and software. The tone was confident but measured, acknowledging near‑term uncertainties around the ramp‑up of new product launches while underscoring long-term growth drivers.

Q4 Revenue and Organic Growth Rebound

Net sales in the fourth quarter rose 5.6% year-on-year to SEK 197 million. Adjusting for foreign exchange, organic growth was a much stronger 12.2%, highlighting solid underlying demand despite a negative FX impact of 6.6%. Management stressed that the quarter confirms a healthy recovery in core markets and validates the company’s commercial execution, even as reported figures are dampened by currency movements.

EBITDA Margin Tops Target

Profitability remained a key highlight. CellaVision posted EBITDA of SEK 65 million in Q4, translating into an EBITDA margin of 33%, comfortably above its 30% long-term target. This margin outperformance signals good cost control and operating leverage, even in a quarter with some unfavorable product mix and FX pressures. Management used the strong margin to support its narrative of a resilient business model capable of investing for growth while still delivering attractive earnings.

Full-Year Growth and Solid Gross Margin

For the full year, CellaVision reported revenue of SEK 759 million, corresponding to 9% organic growth. The full-year gross margin came in at 68%, a solid level that management positions as broadly in line with the company’s structural economics, despite a slightly softer Q4 margin. The figures reinforce that 2025 (company fiscal year in the call context) was a year of steady expansion rather than a one-off spike, giving investors comfort on the underlying trajectory.

Record Americas Performance Drives Growth

The Americas region emerged as the star performer. Q4 revenue in the Americas hit an all-time high of SEK 90 million, with organic growth around 50%—and the CEO even cited a 58% organic uplift in some references. Momentum is particularly strong in the U.S., where integrated network opportunities are driving larger system placements. This record performance underscores how CellaVision’s solutions are increasingly being adopted across larger hospital systems and networks, positioning the Americas as a key growth engine going into 2026.

Instrument Sales Rebound and Large Placements Improve

Instrument revenue rose 8% year-on-year in the quarter to SEK 126 million, reflecting a recovery in capital equipment demand. Management highlighted a rebound in large integrated placements and noted that order-to-install timelines are now typically around two to six months, signaling improving execution and logistics. This recovery in high-value instruments is critical because it seeds future recurring revenues from reagents and services, reinforcing the installed-base growth story.

Bone Marrow CE Mark Unlocks a New Growth Vertical

A major regulatory milestone was the achievement of CE Mark (Class C, IVDR) for CellaVision’s bone marrow aspirate application. This approval paves the way for European commercial launches starting in 2026, with initial revenues expected from the second half, and management’s ambition centered around a Q4 ramp. While not a near-term revenue driver, the bone marrow application is strategically important, expanding CellaVision’s addressable market within hematology and deepening its value proposition in advanced diagnostics.

Software 7.2 and DI-60 Throughput Boost

CellaVision has successfully validated a major software upgrade (version 7.2) at a customer site, integrating it with the DI-60 platform to enhance throughput and user experience. The new software will be bundled into the instrument offering rather than sold separately, both to protect and upgrade the installed base and to support future placements. Management also indicated that instrument price increases are planned, with software functioning as a value-enhancing feature, potentially supporting revenue per unit and competitive positioning.

Strategic R&D Investment and Capitalization

R&D remains a significant focus area. In Q4, R&D spending reached SEK 37 million, equal to 19% of sales, underlining the company’s innovation-led strategy. About SEK 15 million of that was capitalized, roughly half the quarterly R&D spend, as key projects like the bone marrow application move closer to commercialization. Management framed this capitalization and the phased transition to depreciation as part of a deliberate portfolio of development initiatives designed to sustain long-term growth.

Strong Cash Generation and Low Leverage

CellaVision continues to generate healthy cash flows. Operating cash flow in Q4 was SEK 51 million, with total cash flow for the quarter at SEK 30 million, leading to a year-end cash balance of SEK 188 million. Financing activity was limited and debt remains minimal, leaving the balance sheet largely unlevered. This financial flexibility supports ongoing R&D investment, expansion initiatives and shareholder returns without relying heavily on external financing.

Dividend Increase Signals Confidence

Reflecting confidence in its cash-generative profile and capital allocation discipline, the board proposed a dividend increase from SEK 2.50 to SEK 2.75 per share. For investors, the higher payout underscores management’s belief in the durability of earnings and cash flow, even as the company continues to invest heavily in product development and global expansion.

Hematology Reagents Growth and Early APAC Traction

Within consumables, the core hematology reagent portfolio delivered around 10% growth in key markets, reinforcing the strength of CellaVision’s recurring revenue model. In APAC, hematology reagent revenue, while still modest in absolute terms, increased from SEK 1.4 million to SEK 2.0 million year-on-year in Q4, more than doubling and indicating early traction in that region. These dynamics are important as expanding reagent penetration on the installed base is a major driver of long-term margin and revenue visibility.

China Manufacturing Enhances Local Market Access

CellaVision’s integrated system manufacturing in China is becoming strategically important. Local production and registration enable the company to participate in domestic tenders that require local content, a key entry barrier in the market. This capability positions the company to capture a larger share of Chinese hospital and lab automation projects over time and supports the broader APAC growth thesis beyond the shorter-term volatility seen in quarterly results.

APAC Softness and Tough Comparables

Despite the structural opportunity, the APAC region had a weak quarter. Q4 revenue in APAC was SEK 28 million, representing an organic decline of roughly 40% compared with the same period last year. Management attributed this mainly to an exceptionally strong comparable quarter driven by a one-off tender in New South Wales and shipment phasing rather than structural demand deterioration. Still, the magnitude of the decline illustrates the region’s sensitivity to large orders and tender timing, which can distort short-term growth rates.

Reagents and Software Mix Pressure in Q4

Reagent revenues were flat to down slightly (around -2%) in Q4 despite 6% growth year-to-date, while software and other revenues fell sharply. This decline reflected the absence of a large APAC tender booked in the prior year and adverse FX effects, which together created an unfavorable mix that weighed on the quarter’s profitability. Management acknowledged that this softer performance in reagents and software is a notable near-term headwind but emphasized solid underlying demand trends over the full year.

Gross Margin Hit by FX and Product Mix

Q4 gross margin slipped to 67%, a touch below the company’s usual level and the 68% delivered for the full year. The dip was attributed mainly to the weaker mix in software and other high-margin items, as well as FX headwinds, which cumulatively shaved off part of the margin. Management also noted that FX had a 6.6% negative impact on reported growth for the year, underscoring the company’s exposure to currency movements as it expands globally.

Depreciation from Capitalized R&D to Temper Margins

As capitalized development projects like the bone marrow application transition into the commercialization phase, associated depreciation will begin hitting the income statement. Management estimated this will reduce gross margin by roughly one percentage point as depreciation ramps up. Investors should therefore expect some mechanical pressure on reported margins even if underlying economics remain strong, reflecting the accounting life-cycle of past R&D investments rather than a deterioration in business fundamentals.

Non-Hematology Lines Weigh on Organic Growth

Not all product lines are performing equally well. CellaVision highlighted that some non-hematology product lines have underperformed and thereby dragged down overall organic growth. While the company did not detail specific segments, management’s comments suggest that the core hematology business is stronger than the consolidated numbers indicate, and that improving or repositioning these weaker lines represents a potential upside lever for future growth metrics.

New Products Offer Long-Term Upside but Near-Term Uncertainty

The company framed both the bone marrow application and methanol-free reagents as significant strategic opportunities with cautious expectations for the near term. Even though the bone marrow application has secured its CE Mark, management expects only limited contributions in early 2026, with meaningful revenues starting in the second half of that year and an ambition for more visible impact in Q4. Similarly, methanol-free stains will roll out in the U.S. in 2026 but are projected to contribute only modest revenue initially, given the need for protocol adjustments, customer trials and gradual adoption. This conservative stance points to long-term upside but also to near-term revenue uncertainty around these launches.

Methanol-Free Stain Cannibalization Risk in Europe

In Europe, the introduction of methanol-free stains is expected to improve the product offering and align with evolving safety and regulatory preferences, but it may also cannibalize volumes of existing stains as customers convert. As a result, near-term net reagent revenue uplift could be muted despite technological progress. Management’s messaging suggests that the goal is to defend and enhance the installed base and long-term relevance, even if the immediate financial impact is more neutral.

R&D and Capitalization to Remain Variable

R&D spending in Q4, at SEK 37 million, was down versus the prior-year quarter, but management warned that R&D costs are likely to increase again in 2026. Capitalization rates are expected to remain at similar levels, leading to quarter-to-quarter volatility in reported R&D expense and margins as projects move through different stages. For investors, this implies that margin trends will need to be interpreted in light of the company’s development cycle and accounting treatment of R&D rather than as simple indicators of cost discipline.

Forward Outlook: Growth Momentum with Managed Margin Headwinds

Management did not issue a formal numerical revenue guidance for 2026 but laid out clear directional drivers. They expect momentum in the Americas to remain strong, with healthy order intake and shipments into the first half of 2026. The rollout of software 7.2 bundled with DI-60, accompanied by instrument price increases, should support the value of new placements, though the software itself will not be sold as an incremental line item. The CE-marked bone marrow application is expected to start contributing revenue in the second half of 2026, with ambitions focused on Q4, while methanol-free reagents will be launched and scaled during 2026 but with limited financial impact in that year. Management also signaled continued high R&D investment with a similar capitalization rate and cautioned that gross margins may face near-term pressure from FX, product mix shifts and new depreciation associated with capitalized projects—roughly a one percentage-point headwind. Overall, the outlook is for steady growth with some manageable profitability friction as strategic investments enter their commercialization phase.

CellaVision’s earnings call showcased a company balancing strong current performance with significant investment in its future product portfolio. Robust organic growth, record results in the Americas, healthy cash generation and a higher dividend underpin a generally positive investment narrative. At the same time, APAC volatility, margin pressures from FX and mix, and cautious expectations around the near-term revenue impact of new launches add nuance to the story. For investors, the key takeaway is that CellaVision appears well positioned for continued expansion in its core hematology markets while methodically building new growth pillars, albeit with some short-term noise in regional and margin metrics along the way.